372 related articles for article (PubMed ID: 25954851)
21. Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan.
Kanda T; Yasui S; Nakamura M; Suzuki E; Arai M; Haga Y; Sasaki R; Wu S; Nakamoto S; Imazeki F; Yokosuka O
Int J Med Sci; 2016; 13(6):418-23. PubMed ID: 27279790
[TBL] [Abstract][Full Text] [Related]
22. Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures.
Jeong Y; Jin B; Lee HW; Park HJ; Park JY; Kim DY; Han KH; Ahn SH; Kim S
J Viral Hepat; 2018 Nov; 25(11):1251-1259. PubMed ID: 29768695
[TBL] [Abstract][Full Text] [Related]
23. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K
Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551
[TBL] [Abstract][Full Text] [Related]
24. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
[TBL] [Abstract][Full Text] [Related]
25. Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.
Itakura J; Kurosaki M; Hasebe C; Osaki Y; Joko K; Yagisawa H; Sakita S; Okushin H; Satou T; Hisai H; Abe T; Tsuji K; Tamada T; Kobashi H; Mitsuda A; Ide Y; Ogawa C; Tsuruta S; Takaguchi K; Murakawa M; Asahina Y; Enomoto N; Izumi N
PLoS One; 2016; 11(10):e0165339. PubMed ID: 27776192
[TBL] [Abstract][Full Text] [Related]
26. Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test.
Jang ES; Kim KA; Kim YS; Kim IH; Lee BS; Lee YJ; Chung WJ; Jeong SH
J Med Virol; 2019 Dec; 91(12):2158-2165. PubMed ID: 31452206
[TBL] [Abstract][Full Text] [Related]
27. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.
Zhou N; Han Z; Hartman-Neumann S; DeGray B; Ueland J; Vellucci V; Hernandez D; McPhee F
J Antimicrob Chemother; 2016 Dec; 71(12):3495-3505. PubMed ID: 27605597
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Lau G; Benhamou Y; Chen G; Li J; Shao Q; Ji D; Li F; Li B; Liu J; Hou J; Sun J; Wang C; Chen J; Wu V; Wong A; Wong CL; Tsang ST; Wang Y; Bassit L; Tao S; Jiang Y; Hsiao HM; Ke R; Perelson AS; Schinazi RF
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):97-104. PubMed ID: 27917405
[TBL] [Abstract][Full Text] [Related]
29. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.
McPhee F; Hernandez D; Zhou N; Ueland J; Yu F; Vellucci V; Huang X; Wang X; Ishikawa H; Karino Y; Kumada H
Antivir Ther; 2018; 23(1):53-66. PubMed ID: 28594332
[TBL] [Abstract][Full Text] [Related]
30. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.
Kao JH; Lee YJ; Heo J; Ahn SH; Lim YS; Peng CY; Chang TT; Torbeyns A; Hughes E; Bhore R; Noviello S
Liver Int; 2016 Oct; 36(10):1433-41. PubMed ID: 27009831
[TBL] [Abstract][Full Text] [Related]
31. Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing.
Bartolini B; Lionetti R; Giombini E; Sias C; Taibi C; Montalbano M; D'Offizi G; McPhee F; Hughes EA; Zhou N; Ippolito G; Garbuglia AR; Capobianchi MR
J Clin Virol; 2015 May; 66():38-43. PubMed ID: 25866334
[TBL] [Abstract][Full Text] [Related]
32. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
Wei L; Zhang M; Xu M; Chuang WL; Lu W; Xie W; Jia Z; Gong G; Li Y; Bae SH; Yang YF; Xie Q; Lin S; Chen X; Niu J; Jia J; Garimella T; Torbeyns A; McPhee F; Treitel M; Yin PD; Mo L
J Gastroenterol Hepatol; 2016 Nov; 31(11):1860-1867. PubMed ID: 27003037
[TBL] [Abstract][Full Text] [Related]
33. The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.
Hayes CN; Imamura M; Chayama K
Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):103-113. PubMed ID: 27936974
[TBL] [Abstract][Full Text] [Related]
34. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
Takeda H; Ueda Y; Inuzuka T; Yamashita Y; Osaki Y; Nasu A; Umeda M; Takemura R; Seno H; Sekine A; Marusawa H
Sci Rep; 2017 Mar; 7():45605. PubMed ID: 28361915
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.
Hirashima N; Iwase H; Shimada M; Ryuge N; Imamura J; Ikeda H; Tanaka Y; Matsumoto N; Okuse C; Itoh F; Yokomaku Y; Watanabe T
Clin J Gastroenterol; 2017 Feb; 10(1):41-46. PubMed ID: 27766544
[TBL] [Abstract][Full Text] [Related]
36. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study.
Shin SK; Lee JW; Ra H; Kwon OS; Shin JB; Jin YJ; Lee S; Han KJ; Kim YN; Kim TH; Kim YS; Kim JH
J Korean Med Sci; 2019 Oct; 34(41):e264. PubMed ID: 31650719
[TBL] [Abstract][Full Text] [Related]
37. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
Kai Y; Hikita H; Tatsumi T; Nakabori T; Saito Y; Morishita N; Tanaka S; Nawa T; Oze T; Sakamori R; Yakushijin T; Hiramatsu N; Suemizu H; Takehara T
J Gastroenterol; 2015 Nov; 50(11):1145-51. PubMed ID: 26208695
[TBL] [Abstract][Full Text] [Related]
38. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.
McPhee F; Friborg J; Levine S; Chen C; Falk P; Yu F; Hernandez D; Lee MS; Chaniewski S; Sheaffer AK; Pasquinelli C
Antimicrob Agents Chemother; 2012 Jul; 56(7):3670-81. PubMed ID: 22508297
[TBL] [Abstract][Full Text] [Related]
39. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.
Kan H; Imamura M; Uchida T; Hiraga N; Hayes CN; Tsuge M; Abe H; Aikata H; Makokha GN; Chowdhury S; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
J Infect Dis; 2016 Dec; 214(11):1687-1694. PubMed ID: 27651415
[TBL] [Abstract][Full Text] [Related]
40. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
Saito Y; Imamura M; Uchida T; Osawa M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Serikawa M; Aikata H; Abe-Chayama H; Hayes CN; Chayama K
J Med Virol; 2020 Feb; 92(2):210-218. PubMed ID: 31584207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]